P. Kumar

发表

Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine

F. Clubb, D. Rao, N. Senzer, 2013, Cancer Gene Therapy.

Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression

T. Tan, J. Thiery, B. Janji, 2014, Oncogene.

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

N. Senzer, J. Nemunaitis, B. Pappen, 2009, Cancer Gene Therapy.

Proof concept for clinical justification of network mapping for personalized cancer therapeutics

I. Khalil, C. Hill, D. Rao, 2007, Cancer Gene Therapy.

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity

A. Katakam, W. Storkus, H. Okada, 2009, Cancer Gene Therapy.

Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform

D. Rao, N. Senzer, J. Nemunaitis, 2014, Cancer Gene Therapy.

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

N. Senzer, J. Nemunaitis, B. Pappen, 2013, Gene Therapy.

Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference

D. Rao, N. Senzer, J. Nemunaitis, 2010, Cancer Gene Therapy.

Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo

P. Glazer, W. Saltzman, K. Anandalingam, 2012, Gene Therapy.